Home Metabolism LPL Receptor

LPL Receptor

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR
Cat.No. Product Name Information Product Use Citations Product Validations
S5002 FTY720 (Fingolimod) Hydrochloride Fingolimod (FTY720, Fingolimod Hydrochloride) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells. Please use saline solution rather than PBS for dilutions. PBS may cause precipitation.
Cancer Cell, 2025, S1535-6108(25)00319-8
Nat Commun, 2025, 16(1):9175
Nat Commun, 2025, 16(1):1826
Verified customer review of FTY720 (Fingolimod) Hydrochloride
S4578 Tyloxapol Tyloxapol (Triton WR1339) is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surfactant to aid liquefaction, removal of mucopurulent and bronchopulmonary secretions. It also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.This compound can be used to induce animal models of Hyperlipidemia, Atherosclerosis.
iScience, 2022, 25(10):105068
Front Cell Dev Biol, 2022, 10:808140
bioRxiv, 2020, 2020/9/20.4.7.30734
E7476New TY-52156 TY-52156 is an S1P3 receptor antagonist with a Ki of 110 nM.
S7177 PF-543 hydrochloride PF-543 hydrochloride, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform. This compound induces apoptosis, necrosis, and autophagy.
Cell Death Discov, 2025, 11(1):29
FASEB J, 2025, 39(12):e70768
Sci Rep, 2025, 15(1):9786
Verified customer review of PF-543 hydrochloride
S5950 Fingolimod (FTY-720) Fingolimod (FTY-720) is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis.
Neuropharmacology, June 2017, 1-14
Theranostics, June 13, 2018, 3824-3840
Acta Pharmaceutica Sinica B, January 2025, 314-330
S1315 Ki16425 Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM in RH7777 cell lines, respectively, shows no activity at LPA4, LPA5, LPA6.
Frontiers in Pharmacology, September 29, 2021, 706240
Frontiers in Cell and Developmental Biology, October 22, 2025, 1652740
International Journal of Molecular Medicine, February 15, 2016, 468-74
Verified customer review of Ki16425
S7179 Siponimod (BAF312) Siponimod (BAF312) is a next-generation S1P receptor agonist, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, and it exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. This compound has reached Phase 3.
Cell Death Dis, 2025, 16(1):282
Cancers (Basel), 2024, 16(3)574
J Neuroinflammation, 2023, 20(1):35
Verified customer review of Siponimod (BAF312)
S7952 Ozanimod Ozanimod is a selective oral S1P Receptor 1 modulator. Phase 3.
Nat Commun, 2025, 16(1):1826
Front Immunol, 2024, 15:1230735
FASEB Journal, 2022 Feb, e22132
S7182 JTE 013 JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.
eLife, September 17, 2020, e60541
Cancer Management and Research, August 26, 2020, 7857-7865
Cell Death Dis, 2025, 16(1):282
S8241 Ponesimod (ACT-128800) Ponesimod (ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM.
Cancers (Basel), 2024, 16(3)574
EBioMedicine, 2023, 94:104713
Int J Mol Sci, 2022, 23(18)10311